522 related articles for article (PubMed ID: 14515016)
1. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
2. Heparin ablates force development during platelet mediated clot retraction.
Carr ME; Carr SL; Greilich PE
Thromb Haemost; 1996 Apr; 75(4):674-8. PubMed ID: 8743198
[TBL] [Abstract][Full Text] [Related]
3. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation.
Carr ME; Martin EJ; Carr SL
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):193-7. PubMed ID: 11943932
[TBL] [Abstract][Full Text] [Related]
4. Development of platelet contractile force as a research and clinical measure of platelet function.
Carr ME
Cell Biochem Biophys; 2003; 38(1):55-78. PubMed ID: 12663942
[TBL] [Abstract][Full Text] [Related]
5. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
8. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
Bolliger D; Szlam F; Azran M; Koyama K; Levy JH; Molinaro RJ; Tanaka KA
Anesth Analg; 2010 Sep; 111(3):601-8. PubMed ID: 20686004
[TBL] [Abstract][Full Text] [Related]
9. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
10. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
11. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Carr ME; Carr SL; Tildon T; Fisher LM; Martin EJ
J Thromb Haemost; 2003 Feb; 1(2):243-9. PubMed ID: 12871496
[TBL] [Abstract][Full Text] [Related]
12. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
14. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
Herren T; Straub PW; Haeberli A
Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
Meddahi S; Bara L; Fessi H; Samama MM
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
[TBL] [Abstract][Full Text] [Related]
16. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.
Nielsen VG
Ann Thorac Surg; 2006 May; 81(5):1720-7. PubMed ID: 16631662
[TBL] [Abstract][Full Text] [Related]
17. Platelet microtubules in clot structure formation and contractile force generation: investigation of a controversy.
Jen CJ; McIntire LV
Thromb Haemost; 1986 Aug; 56(1):23-7. PubMed ID: 2877507
[TBL] [Abstract][Full Text] [Related]
18. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
19. Concentration effects of platelets, fibrinogen and thrombin on platelet aggregation and fibrin clotting.
Chao FC; Tullis JL; Kenney DM; Conneely GS; Doyle JR
Thromb Diath Haemorrh; 1974 Sep; 32(1):216-31. PubMed ID: 4454041
[TBL] [Abstract][Full Text] [Related]
20. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
